65,786 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Neo Ivy Capital Management

Neo Ivy Capital Management bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 65,786 shares of the biopharmaceutical company’s stock, valued at approximately $702,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Assenagon Asset Management S.A. bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth approximately $8,386,000. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Fiera Capital Corp grew its stake in shares of Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Amicus Therapeutics by 10.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after purchasing an additional 242,672 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Amicus Therapeutics by 51.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock valued at $2,381,000 after acquiring an additional 75,807 shares during the period.

Amicus Therapeutics Stock Up 0.3 %

Shares of FOLD stock opened at $10.16 on Thursday. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm has a market capitalization of $3.04 billion, a PE ratio of -29.88 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock’s 50-day simple moving average is $10.55 and its 200-day simple moving average is $10.61.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $11.46, for a total value of $85,950.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,161,054.84. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 30,401 shares of company stock worth $339,363. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Cantor Fitzgerald boosted their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Finally, Morgan Stanley lowered their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.63.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.